"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

MCLEAN, VA / ACCESSWIRE / December 10, 2024 / Dr. Amir Bajoghli and his colleagues have recently published an insightful case ...

The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately ...

Briquilimab is a monoclonal antibody commercialized by Jasper Therapeutics, with a leading Phase II program in Severe Combined Immune Deficiency (SCID).

Diagnosing CSU can be difficult for a few main reasons, including the following: CSU is often misdiagnosed because hives are ...

About half of people with "chronic spontaneous urticaria," or CSU, the most common type of chronic hives, experience what ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

ORLANDO -- First-dose reactions to IV ustekinumab (Stelara) may be related to IgE recognition of a carbohydrate allergen in ...

Skin cells called mast cells are key players in the inflammation and itchiness that can plague folks with these skin ailments ...

Ligelizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in Food Allergy.

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of ...